88 related articles for article (PubMed ID: 28259909)
1. Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities.
Xu X; Zhang M; Xu F; Jiang S
Mol Cancer; 2020 Nov; 19(1):165. PubMed ID: 33234169
[TBL] [Abstract][Full Text] [Related]
2. Mechanical effects modulate drug resistance in MCF-7-derived organoids: Insights into the wnt/β-catenin pathway.
Karimifard SA; Salehzadeh-Yazdi A; Taghizadeh-Tabarsi R; Akbari-Birgani S
Biochem Biophys Res Commun; 2024 Feb; 695():149420. PubMed ID: 38154263
[TBL] [Abstract][Full Text] [Related]
3. Abnormal Long Non-Coding RNAs Expression Patterns Have the Potential Ability for Predicting Survival and Treatment Response in Breast Cancer.
Pavanelli AC; Mangone FR; Barros LRC; Machado-Rugolo J; Capelozzi VL; Nagai MA
Genes (Basel); 2021 Jun; 12(7):. PubMed ID: 34209776
[TBL] [Abstract][Full Text] [Related]
4. Targeting the Wnt/β-catenin signaling pathway in cancer.
Zhang Y; Wang X
J Hematol Oncol; 2020 Dec; 13(1):165. PubMed ID: 33276800
[TBL] [Abstract][Full Text] [Related]
5. miR-601 inhibits proliferation, migration and invasion of prostate cancer stem cells by targeting KRT5 to inactivate the Wnt signaling pathway.
Du H; Wang X; Dong R; Hu D; Xiong Y
Int J Clin Exp Pathol; 2019; 12(12):4361-4379. PubMed ID: 31933840
[TBL] [Abstract][Full Text] [Related]
6. Identification and characterization of biomarkers and their functions for docetaxel-resistant prostate cancer cells.
Deng L; Gu X; Zeng T; Xu F; Dong Z; Liu C; Chao H
Oncol Lett; 2019 Sep; 18(3):3236-3248. PubMed ID: 31452801
[TBL] [Abstract][Full Text] [Related]
7. Primary hyperparathyroidism in prostate cancer: guilty or not guilty?
Mazziotti G; Frara S; Mosca A
Endocrine; 2018 Nov; 62(2):271-273. PubMed ID: 29846903
[No Abstract] [Full Text] [Related]
8. Wnt signaling pathway in non-small cell lung cancer.
Stewart DJ
J Natl Cancer Inst; 2014 Jan; 106(1):djt356. PubMed ID: 24309006
[TBL] [Abstract][Full Text] [Related]
9. Salinomycin: A new paradigm in cancer therapy.
Dewangan J; Srivastava S; Rath SK
Tumour Biol; 2017 Mar; 39(3):1010428317695035. PubMed ID: 28349817
[TBL] [Abstract][Full Text] [Related]
10. Prostate apoptosis response 4 (PAR4) expression modulates WNT signaling pathways in MCF7 breast cancer cells: A possible mechanism underlying PAR4-mediated docetaxel chemosensitivity.
de Bessa Garcia SA; Pavanelli AC; Cruz E Melo N; Nagai MA
Int J Mol Med; 2017 Apr; 39(4):809-818. PubMed ID: 28259909
[TBL] [Abstract][Full Text] [Related]
11. The Wnt non-canonical signaling modulates cabazitaxel sensitivity in prostate cancer cells.
Sennoune SR; Nelius T; Jarvis C; Pruitt K; Kottapalli KR; Filleur S
PLoS One; 2020; 15(6):e0234078. PubMed ID: 32484838
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer cells respond differently to docetaxel depending on their phenotype and on survivin upregulation.
De Iuliis F; Salerno G; Giuffrida A; Milana B; Taglieri L; Rubinacci G; Giantulli S; Terella F; Silvestri I; Scarpa S
Tumour Biol; 2016 Feb; 37(2):2603-11. PubMed ID: 26392111
[TBL] [Abstract][Full Text] [Related]
13. Acquisition of docetaxel resistance in breast cancer cells reveals upregulation of ABCB1 expression as a key mediator of resistance accompanied by discrete upregulation of other specific genes and pathways.
Hansen SN; Westergaard D; Thomsen MB; Vistesen M; Do KN; Fogh L; Belling KC; Wang J; Yang H; Gupta R; Ditzel HJ; Moreira J; Brünner N; Stenvang J; Schrohl AS
Tumour Biol; 2015 Jun; 36(6):4327-38. PubMed ID: 25596703
[TBL] [Abstract][Full Text] [Related]
14. miRNA-34a is associated with docetaxel resistance in human breast cancer cells.
Kastl L; Brown I; Schofield AC
Breast Cancer Res Treat; 2012 Jan; 131(2):445-54. PubMed ID: 21399894
[TBL] [Abstract][Full Text] [Related]
15. Methylation of RASSF10 promotes cell proliferation and serves as a docetaxel resistant marker in human breast cancer.
Dong T; Zhang M; Dong Y; Herman JG; van Engeland M; Zhong G; Guo M
Discov Med; 2015 Nov; 20(111):261-71. PubMed ID: 26645898
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
